Key Points
- CEO Daniel Patrick O'day sold 10,000 shares on Nov. 28 at an average price of $126.54 for $1.265M, trimming his stake to 571,203 shares (a 1.72% decrease); this follows two prior 10,000-share sales in September and October.
- Gilead beat quarterly expectations with EPS of $2.47 vs. $2.16 and revenue of $7.77B vs. $7.42B, set FY2025 guidance of $8.05–$8.25 EPS, and announced a $0.79 quarterly dividend (annual $3.16, ~2.5% yield).
- Analyst sentiment is positive overall — a consensus "Moderate Buy" with an average price target of $130.65 and several recent upgrades/coverage initiations (some $140 targets) — while institutions own about 83.7% of the stock.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) Director Kelly Kramer sold 2,805 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the transaction, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Gilead Sciences Stock Down 1.2%
Shares of Gilead Sciences stock opened at $124.33 on Tuesday. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70. The company has a market cap of $154.25 billion, a P/E ratio of 24.77, a PEG ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a fifty day moving average of $120.11 and a two-hundred day moving average of $114.87.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences's dividend payout ratio is 48.99%.
Institutional Investors Weigh In On Gilead Sciences
Large investors have recently added to or reduced their stakes in the business. One Wealth Advisors LLC grew its stake in Gilead Sciences by 34.8% in the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock worth $1,016,000 after acquiring an additional 2,364 shares during the period. Sivik Global Healthcare LLC boosted its holdings in shares of Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company's stock worth $5,544,000 after purchasing an additional 10,000 shares during the last quarter. Ariel Investments LLC grew its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after purchasing an additional 30,630 shares during the period. Simplify Asset Management Inc. increased its stake in Gilead Sciences by 148.6% in the second quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company's stock valued at $5,864,000 after purchasing an additional 31,618 shares during the last quarter. Finally, VeraBank N.A. acquired a new position in Gilead Sciences in the second quarter valued at $397,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on GILD. Truist Financial began coverage on Gilead Sciences in a research note on Monday, November 24th. They issued a "buy" rating and a $140.00 price target on the stock. Citigroup boosted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Wednesday, October 8th. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a "neutral" rating in a report on Friday, October 31st. Wall Street Zen upgraded shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 15th. Finally, Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a "sector perform" rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $130.65.
View Our Latest Report on GILD
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
